美股市场个股详情
NAUT Nautilus Biotechnology
- 2.270
- -0.020-0.87%
交易中 08/09 09:33 (美东)
2.85亿总市值-4127市盈率TTM
2.290最高价2.260最低价605股成交量2.290今开2.290昨收1375.37成交额0.00%换手率亏损市盈率(静)1.25亿总股本4.00052周最高1.21市净率9487.26万流通值2.19052周最低--股息TTM4179.41万流通股25.886历史最高--股息率TTM1.31%振幅1.500历史最低2.273平均价1股每手
Nautilus Biotechnology股票讨论区
登录发表评论
![[睡]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "睡"){kind=small}
$Inhibikase Therapeutics (IKT.US)$
$Inhibikase Therapeutics (IKT.US)$
$Inhibikase Therapeutics (IKT.US)$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
The Company is completing 13-week pivotal toxicology studies to be submitted to the FDA for review in August.
CEO excised options
$CohBar (CWBR.US)$
$CohBar (CWBR.US)$
..........................................
$Fulcrum Therapeutics (FULC.US)$
$Inhibikase Therapeutics (IKT.US)$
$Inhibikase Therapeutics (IKT.US)$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
The Company is completing 13-week pivotal toxicology studies to be submitted to the FDA for review in August.
CEO excised options
$CohBar (CWBR.US)$
$CohBar (CWBR.US)$
..........................................
$Fulcrum Therapeutics (FULC.US)$
7
1
暂无评论
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
Klim5115 : 通过投资致富和致富的好处
HunterSparks : Nextdoor彻底改变了社区生活。将在与SPAC co KVSB合并后上市，股票代码为KIND。股票代码非常适合其应用程序。可以在上市前通过KVSB获得曝光